Drug Trial Radar · NCT05633667
Study of Novel Treatment Combinations in Patients With Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
192
Actual
Start
Mar 16, 2023
Primary completion
Sep 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Arcus Biosciences, Inc.
- First posted
- Dec 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.
Conditions
- Lung Cancer
- Advanced or Metastatic Non-Small-Cell Lung Cancer
- Resectable Non-Small-Cell Lung Cancer
Interventions
Zimberelimab (ZIM)Drug
Administered intravenously
Domvanalimab (DOM)Drug
Administered intravenously
Sacituzumab govitecan-hziy (SG)Drug
Administered intravenously
Etrumadenant (ETRUMA)Drug
Administered orally
CarboplatinDrug
Administered intravenously
CisplatinDrug
Administered intravenously
PemetrexedDrug
Administered intravenously
PaclitaxelDrug
Administered intravenously
Nab-paclitaxelDrug
Administered intravenously
DocetaxelDrug
Administered intravenously
NivolumabDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Substudies 01 and 02: Objective Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Up to 5 years
- Substudy 03: Complete Pathological Response (pCR) RateTime frame: Up to 5 years
Locations
89 sites in 8 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates,Substudy-02
Tucson, Arizona
Fort Wayne Medical Oncology and Hematology, Inc.,Substudy-03
Fort Wayne, Indiana
Baptist Health Lexington,Substudy-03
Lexington, Kentucky
Washington University School of Medicine - Siteman Cancer Center,Substudy-01
St Louis, Missouri
Washington University School of Medicine - Siteman Cancer Center,Substudy-02
St Louis, Missouri
Washington University School of Medicine - Siteman Cancer Center,Substudy-03
St Louis, Missouri
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri
Oncology Hematology Care Clinical Trials, LLC,Substudy-01
Cincinnati, Ohio
Oncology Hematology Care Clinical Trials, LLC,Substudy-02
Cincinnati, Ohio
Oncology Associates of Oregon, PC,Substudy-01
Eugene, Oregon
Oncology Associates of Oregon, PC,Substudy-02
Eugene, Oregon
Fundação Pio XII - Hospital de Amor,Substudy-01
Barretos, Brazil
Centro Gaúcho Integrado de Oncologia Hematologia, Ensino e Pesquisa Ltda./Hospital Mãe de Deus,Substudy-03
Porto Alegre, Brazil
Hospital Mae de Deus,Substudy-01
Porto Alegre, Brazil
Hospital Mae de Deus
Porto Alegre, Brazil
Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-01
Porto Alegre, Brazil
Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03
Porto Alegre, Brazil
BP-A Beneficencia Portuguesa De Sao Paulo,Substudy-01
São Paulo, Brazil
Fundação Antonio Prudente - Hospital do Câncer AC Camargo,Substudy-01
São Paulo, Brazil
Fundação Antonio Prudente/A.C. Camargo Cancer Center,Substudy-03
São Paulo, Brazil
Real e Benemérita Associação Portuguesa de Beneficência/Hospital Beneficência Portuguesa de São Paulo (Hospital BP),Substudy-03
São Paulo, Brazil
Queen Mary Hospital,Substudy-01
Hong Kong, Hong Kong
Queen Mary Hospital,Substudy-02
Hong Kong, Hong Kong
Queen Elizabeth Hospital,Substudy-01
Hong Kong, Hong Kong
Queen Elizabeth Hospital,Substudy-02
Hong Kong, Hong Kong
Prince of Wales Hospital,Substudy-01
New Territories, Hong Kong
Prince of Wales Hospital,Substudy-02
New Territories, Hong Kong
Rambam Health Care Campus,Substudy-01
Haifa, Israel
Rambam Health Care Campus,Substudy-02
Haifa, Israel
Rambam Health Care Campus,Substudy-03
Haifa, Israel
Shaare Zedek Medical Center,Substudy-01
Jerusalem, Israel
Shaare Zedek Medical Center,Substudy-02
Jerusalem, Israel
Shaare Zedek Medical Center,Substudy-03
Jerusalem, Israel
Hadassah Medical Center,Substudy-01
Jerusalem, Israel
Hadassah University Medical Center,Substudy-03
Jerusalem, Israel
Tel Aviv Sourasky Medical Center,Substudy-01
Tel Aviv, Israel
Tel Aviv Sourasky Medical Center,Substudy-02
Tel Aviv, Israel
Tel-Aviv Sourasky Medical Center,Substudy-03
Tel Aviv, Israel
Chungbuk National University Hospital,Substudy-01
Cheongju-si, South Korea
Chungbuk National University Hospital,Substudy-02
Cheongju-si, South Korea
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.